Back to Search
Start Over
Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement
Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement
- Source :
- Российский кардиологический журнал, Vol 25, Iss 5 (2020)
- Publication Year :
- 2020
- Publisher :
- «FIRMA «SILICEA» LLC, 2020.
-
Abstract
- Relationships and Activities. The Council of Experts was supported by AstraZeneca.
Details
- Language :
- Russian
- ISSN :
- 15604071 and 26187620
- Volume :
- 25
- Issue :
- 5
- Database :
- Directory of Open Access Journals
- Journal :
- Российский кардиологический журнал
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.fcda189d1b94fcebbfc56fead0270a5
- Document Type :
- article
- Full Text :
- https://doi.org/10.15829/1560-4071-2020-3919